Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Rebetol opvejer risiciene til behandling af kronisk hepatitis C, når det anvendes i kombination med peginterferon alfa - 2b til voksne, herunder ikke tidligere behandlede patienter med samtidig klinisk stabil hiv- infektion,
The Committee for Medicinal products for Human Use (CHMP) decided that Rebetol’ s benefits are greater than its risks for treatment of chronic hepatitis C, as part of a combination regimen with peginterferon alfa-2b (adults) including naïve patients with clinically stable HIV co-infection, or